Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 Pretax Margin % is 23.55% as of Mar. 2026, which is 35% above its 10-year median of 17.48. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Jacobson Pharma ranks better than 86.03% on this metric.
The historical rank and industry rank for Jacobson Pharma's Pretax Margin % or its related term are showing as below:
HKSE:02633'
s Pretax Margin % Range Over the Past 10 Years
Min: 14.5 Med: 17.48 Max: 23.69
Current: 23.11
HKSE:02633's Pretax Margin % is ranked better than 86.03% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.21
vs HKSE:02633: 23.11
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Jacobson Pharma Pretax Margin % Related Terms
Jacobson Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a Pretax Margin % of 23.55% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jacobson Pharma and its competitors. This is 35% above median its historical median of 17.48. Over the past decade, Jacobson Pharma's Pretax Margin % has ranged from 14.50 to 23.69. According to the industry distribution chart, Jacobson Pharma ranks #134 out of 959 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Jacobson Pharma's Pretax Margin % too high?
Jacobson Pharma's current Pretax Margin % of 23.55% is 35% above median its 10-year median of 17.48. Over the past 10 years, this metric has ranged from a low of 14.50 to a high of 23.69. The Drug Manufacturers industry median Pretax Margin % is 7.21. Jacobson Pharma's value of 23.55% is 226.6% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #134 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #134 out of 959 companies for Pretax Margin %. This places Jacobson Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.21. Jacobson Pharma's value of 23.55% is 226.6% above this benchmark. Historically, Jacobson Pharma's own Pretax Margin % has ranged from 14.50 to 23.69 over the past decade. While the company's 10-year median is 17.48 vs. the industry median of 7.21, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.21, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current Pretax Margin % of 23.55% is 226.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current Pretax Margin % is 23.55%, which is 35% above median its own 10-year median of 17.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Pretax Margin % is 23.55%, which is 35% above median its 10-year median of 17.48 and 226.6% above the Drug Manufacturers industry median of 7.21. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Pretax Margin % is 23.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Pretax Margin %: 23.55% (35% above median its 10-year median of 17.48)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 226.6% above the Drug Manufacturers median (#134 of 959)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
